Roth Capital Downgrades Tattooed Chef to Neutral, Lowers Price Target to $9
Roth Capital analyst George Kelly downgrades Tattooed Chef (NASDAQ:TTCF) from Buy to Neutral and lowers the price target from $12 to $9.
RBC Capital Downgrades Global Blood Therapeutics to Sector Perform, Raises Price Target to $68.5
RBC Capital analyst Gregory Renza downgrades Global Blood Therapeutics (NASDAQ:GBT) from Outperform to Sector Perform and raises the price target from $60 to $68.5.
Compass Point Downgrades Argo Gr Intl Hldgs to Neutral, Announces $35 Price Target
Compass Point analyst Casey Alexander downgrades Argo Gr Intl Hldgs (NYSE:ARGO) from Buy to Neutral and announces $35 price target.
Barclays Downgrades CRISPR Therapeutics to Equal-Weight, Lowers Price Target to $88
Barclays analyst Gena Wang downgrades CRISPR Therapeutics (NASDAQ:CRSP) from Overweight to Equal-Weight and lowers the price target from $99 to $88.
Deutsche Bank Downgrades Palantir Technologies to Sell, Lowers Price Target to $8
Deutsche Bank analyst Brad Zelnick downgrades Palantir Technologies (NYSE:PLTR) from Hold to Sell and lowers the price target from $11 to $8.
MKM Partners Downgrades Winnebago Industries to Neutral, Announces $67 Price Target
MKM Partners analyst Scott Stember downgrades Winnebago Industries (NYSE:WGO) from Buy to Neutral and announces $67 price target.
Cantor Fitzgerald Downgrades Global Blood Therapeutics to Neutral, Lowers Price Target to $68.5
Cantor Fitzgerald downgrades Global Blood Therapeutics (NASDAQ:GBT) from Overweight to Neutral and lowers the price target from $75 to $68.5.
Cowen & Co. Downgrades Global Blood Therapeutics to Market Perform, Raises Price Target to $68.5
Cowen & Co. analyst Ritu Baral downgrades Global Blood Therapeutics (NASDAQ:GBT) from Outperform to Market Perform and raises the price target from $67 to $68.5.
Truist Securities Downgrades Aemetis to Hold, Announces $12 Price Target
Truist Securities analyst Jordan Levy downgrades Aemetis (NASDAQ:AMTX) from Buy to Hold and announces $12 price target.
Piper Sandler Downgrades Broadmark Realty Capital to Underweight
Piper Sandler analyst Crispin Love downgrades Broadmark Realty Capital (NYSE:BRMK) from Neutral to Underweight.